LUMOSA Board of Directors approved the Cancellation
of Restricted Shares to Employees Stock Awards
Date of events
2022/08/09
To which item it meets
paragraph 11
Statement
1.Date of the board of directors resolution:2022/08/09
2.Reason for capital reduction:
As the vesting conditions of the issuance of restricted stock awards have
not been met by the intended employees, the board of directors has resolved
to withdraw issuance to such employees without compensation and cancel the
full number of the shares.
3.Amount of capital reduction:NTD 550,000
4.Cancelled shares:55,000 shares
5.Capital reduction ratio:0.03%
6.Share capital after capital reduction:NTD 1,630,778,250
7.Scheduled date of the shareholders' meeting:NA
8.Estimated no.of TPEx-listed common shares after issuance
of new shares upon capital reduction:NA
9.Estimated ratio of TPEx-listed common shares after issuance
of new shares upon capital reduction to outstanding common
shares:NA
10.Please explain any countermeasures for lower circulation
in shareholding if the aforesaid estimated no.of TPEx-listed
common shares upon capital reduction does not reach 5 million
and the ratio does not reach 25%:NA
11.Record date of capital reduction:2022/08/09
12.Any other matters that need to be specified:NA
Attachments
Original Link
Original Document
Permalink
Disclaimer
Lumosa Therapeutics Co. Ltd. published this content on 09 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 09:45:07 UTC.
LUMOSA THERAPEUTICS CO., LTD. is a Taiwan-based company principally engaged in the development of new drugs. The Company is engaged in the development of new drugs for unmet medical needs in the fields of central nervous system (CNS), oncology, and inflammatory diseases. The Company is engaged in scientific licensing and new drug development under the reSEARCH and DEVELOPMENT model.
LUMOSA THERAPEUTICS CO., LTD. 
